Results 51 to 60 of about 188,732 (189)

Thyroid ophthalmopathy in an adolescent girl: a case report [PDF]

, 2017
A 14 year old girl presented with protrusion of both the eyes for duration of 3 months and pain, redness and watering of right eye for 20 days. On examination, she was thin built, poorly nourished and the thyroid gland was found to be enlarged. Both eyes
Das, Rajiv Kumar, Devi, Bhanu, Phukan, Shobhana   +2 more
core   +1 more source

Practical Guidelines Management of Graves Ophthalmopathy

Acta Medica Indonesiana, 2020
Graves’ ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves’ disease, based on inflammatory and autoimmune conditions in orbital tissue.
Imam Subekti, Pradana Soewondo, Suharko Soebardi, Budiman Darmowidjojo, Dante Saksono Harbuwono, Dyah Purnamasari, Tri Juli Edi Tarigan, Wismandari Wisnu, Dicky Levenus Tahapary, Farid Kurniawan, M Sidik, Syntia Nusanti, Salmarezka Dewiputri, Hernawita Suharko, Gusti G Suardana, Indrati Suroyo, Vally Wulani, Alvita Dewi Siswoyo, Soehartati Gondhowiardjo, Henry Kodrat   +19 more
doaj   +2 more sources

MODERN APPROACHES TO THE THERAPY OF ENDOCRINE OPHTHALMOPATHY

Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2019
Background: The number of patients with thyroid disease is increasing due to people suffering from Graves' disease, which is often accompanied by endocrine autoimmune ophthalmopathy.
Nikonova L. V., Tishkovskiy S. V., Hadomskaya V. I., Davydchyk E. V., Doroshkevich I. P.   +4 more
doaj   +1 more source

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Thyroid Associated Ophthalmopathy

Delhi Journal of Ophthalmology, 2012
Thyroid associated orbitopathy/ophthalmopathy is an autoimmune disorder. It is most prevalent among females and is usually associated with thyroid dysfunction. Clinical manifestations include soft tissue signs, lid retraction, lid lag, proptosis, restrictive myopathy, corneal exposure and optic neuropathy. Thyroid function tests, thyroid antibodies and
Sonam Angmo Bodh, Saurabh Kamal, Ruchi Goel, Sushil Kumar, Smriti Bansal, Madhu Singh   +5 more
openaire   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

Orbital lymphoma associated with Graves’ disease: A case report [PDF]

Vojnosanitetski Pregled, 2014
Introduction. The presence of bilateral exophthalmos and palpebral, periorbital edema associated with hyperthyroidism is most often considered as an initial sign of Graves’ ophthalmopathy.
Hajduković Zoran, Kuzmić-Janković Snežana, Kljaković-Avramović Tamara, Sekulović Leposava, Tukić Ljiljana   +4 more
doaj   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Diagnosis and treatment of Graves' disease

Медицинский совет, 2014
Graves' disease (Basedow's goiter, exophtalmic goiter) is a systemic autoimmune disease resulting from the production of stimulating antibodies to the thyroid stimulating hormone (TSH) receptor; it is clinically manifested in lesions of the thyroid gland
V. V. Fadeyev
doaj   +1 more source